Vivanta Industries Limited has rescheduled its board meeting originally scheduled for July 24, 2026, to Wednesday, July 29, 2026. The rescheduling is due to heavy rainfall and prevailing adverse weather conditions.
The board meeting agenda includes:
1. Consideration and approval of Unaudited Standalone and Consolidated Financial Results along with Limited Review Report for the quarter ended June 30, 2026
2. Authorization of signatories for signing the Audited Financial Statements for the financial year ended March 31, 2026
3. Note on issuance of duplicate share certificates in lieu of original share certificates reported as lost/misplaced by shareholders
4. Note on business collaboration agreements with Qness Pharmaceuticals, a proprietorship concern, for the manufacture, supply, branding and marketing of pharmaceutical and allied products
5. Note on Corporate Governance Report for the quarter ended June 30, 2026
6. Note on E-Form DPT-3 Return of Deposits for the quarter ended June 30, 2026
7. Any other business with the permission of the Chair
The notice of the board meeting will be made available on the company's website at https://vivantaindustries.com/disclosure/ as per Regulation 46 of SEBI Listing Regulations.
The trading window for dealing in the company's securities remains closed for Directors, Officers, Key Managerial Personnel, and Designated Persons until 48 hours after the declaration of financial results for the quarter ended June 30, 2026, in compliance with SEBI (Prohibition of Insider Trading) Regulations, 2015 and the company's Internal Code for Prohibition of Insider Trading.
This intimation is made under Regulation 29(1)(a) and 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and serves as a continuation to the earlier intimation dated July 21, 2026.